Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient

Laborértékek

• Asthmatic Patient :
  • Underage,
  • Pregnant or breast-feeding women,
  • Adult on guardianship
  • Active smoker (smoked or Inhaled),
  • former smokers (smoked or Inhaled) with a smoking history of ≥10 pack years since less than 5 years.
  • Patient with asthma exacerbation the 4 past weeks before the exploratory visit..
  • Patient treated by long term oral corticosteroids or ongoing biological therapy or stopped within the 3 months before exploratory visit.
  • Patient with severe acute or chronic organ disorder (cardiovascular, respiratory, hepatic, renal, malabsorption)
  • Patient with history of unstable angina,
  • Patient with platelet count abnormality, or primary or acquired thrombopathy, or an aPTT (activated Partial Thromboplastin Time) greater than or equal to 1,5 times normal or patient with a Quick Time \> 26 seconds
  • Patient under a systemic immunomodulatory or immunosuppressive treatment
  • Patient with anticoagulants or anti-platelet aggregating drugs other than D-lysin acetylsalicylate and that could not be suspended before the bronchial fibroscopy.
  • Patient with hypersensitivity to the treatment used during the bronchial fibroscopy: Hydroxyzine, Midazolam, Xylocaine.
  • Patient with AME (Government Medical Assistance),
  • Patient having physical and psychological disabilities to follow the protocol,
  • Patient included in another interventional research protocol,
  • Patient having risk factors of Creutzfeld-Jakob disease

Egyéb

• Controlled sample:
  • Asthmatic patient

• Asthmatic Patient :
  • Male or Female from 18 to 70 years old,
  • Diagnosis of asthma confirmed by
  • Existence of one or more following symptoms over 3 months at least (wheezing dyspnea, wheezing, chronic cough and tightness in the chest…)
  • AND past pulmonary function test showing a reversible obstructive ventilatory syndrome after inhaled short-acting bronchodilators (improvement of FEV1 above 12% and at least 200 mL FEV1 gain compare to pre-bronchodilatator FEV1)
  • AND a removal of the clinically suspected differential diagnoses of asthma (vocal cord dysfunction, Churg-Strauss syndrome etc…). The comorbidities should have been explored and treated or on treatment at enrollment.
  • Subject agreed to participate to the study and the biological samples collection,
  • Subject is affiliate to a social security system.
• Inclusion criteria for severe asthmatic patient :
  • Patient with one of the following criterion will be considered as severe asthmatic patient :
• Patient with a controlled asthma but using high dose of inhaled corticosteroids with another therapeutic classes,
• OR Patient with uncontrolled asthma despite treatment,
• OR Patient with worsening asthma despite treatment.
  • --\>Inclusion criteria for non-severe asthmatic patients :
• Moderate Asthmatic patient without standard of care treatment since at least one week before the exploratory visit.
  • --\>Controlled sample:
• Non asthmatic cadaveric adults